The PACIFIC trial, a phase III, placebo-controlled trial, compared durvalumab—a monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80—with observation after chemoradiotherapy in stage III unresected NSCLC patients10. This evidence concerns the gene CD274 and non-small cell lung carcinoma.